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Type-2 Diabetes (T2D), diabetic complications, and their clinical risk factors harbor a substantial genetic 
component but the genetic factors contributing to overall diabetes mortality remain unknown. Here, 
we examined the association between genetic variants at 21 T2D-susceptibility loci and all-cause 
mortality in an elderly cohort of 542 Italian diabetic patients who were followed for an average of 
12.08 years. Univariate Cox regression analyses detected age, waist-to-hip ratio (WHR), glycosylated 
haemoglobin (HbA1c), diabetes duration, retinopathy, nephropathy, chronic kidney disease (CKD), 
and anaemia as predictors of all-cause mortality. When Cox proportional hazards multivariate models 
adjusted for these factors were run, three erythropoietin (EPO) genetic variants in linkage disequilibrium 
(LD) with each other (rs1617640-T/G, rs507392-T/C and rs551238-A/C) were significantly (False 
Discovery Rate < 0.1) associated with mortality. Haplotype multivariate analysis revealed that patients 
carrying the G-C-C haplotype have an increased probability of survival, while an opposite effect was 
observed among subjects carrying the T-T-A haplotype. Our findings provide evidence that the EPO gene 
is an independent predictor of mortality in patients with T2D. Thus, understanding the mechanisms by 
which the genetic variability of EPO affects the mortality of T2D patients may provide potential targets 
for therapeutic interventions to improve the survival of these patients.
T2D has an estimated prevalence of more than 9% worldwide, with the number of diabetic patients predicted 
to increase over the next ten years particularly due to the growth of the aging population and the increased 
incidence of overweight and obesity1. Patients with T2D have an increased risk of developing microvascular 
and macrovascular complications, which, in turn, are the major cause of cardiovascular deaths in these individ-
uals2. Cancer as well as non-cardiovascular and non-cancer causes have also been reported to increase the risk 
of mortality in diabetic patients compared to nondiabetic subjects3,4. The underlying root factors of the relation-
ship between diabetes complications and mortality are not fully understood and their identification is vital to 
improve health outcomes and reduce premature mortality rates of patients. Recently, an observational cohort 
study reported that modifiable lifestyle habits, such as the quality of food eaten, physical activity, and tobacco 
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and alcohol use, are associated with reduced risk for CKD and mortality in middle-aged individuals with T2D5, 
suggesting that lifestyle behavior might in part account for this relationship. However, findings from several other 
observational studies argue for a more complex link between the main determinants of mortality in diabetic 
patients6–9. For instance, using data on more than 200,000 adults with T2D and after adjusting for multiple con-
founding factors, Kontopantelis et al.8 predicted that U-shaped relationships exist between glycated hemoglobin, 
blood pressure, total cholesterol, and all-cause mortality in diabetic patients. Consistently, a significant associa-
tion between increased mortality and low levels of the above mentioned biological factors has also been reported 
in a large population of very old diabetic subjects (≥80 years of age)9.
T2D, diabetic complications, and their clinical risk factors have a strong genetic component10,11, which, in 
turn, might contribute to a higher risk for mortality. In this regard, previous work showed a significant association 
of three common genetic variants on 9p21, a chromosomal region linked to T2D and cardiovascular disease, with 
the mortality rate in Dutch diabetic patients12. Association with all-cause mortality was also reported for a variant 
at the glutamate-ammonia ligase (GLUL) locus, a marker of increased CHD risk13. Furthermore, a genetic risk 
score that includes 38 common T2D risk variants was found associated with mortality in an ethnic- and body 
weight-specific manner14. However, despite these findings, little is still known about the genetic factors that pre-
dispose to mortality in T2D patients. To this end, we performed a population-based, prospective cohort analysis 
to identify genetic risk factors for all-cause mortality in a cohort of central Italian diabetic patients, who were 
previously tested for genetic associations with T2D and its complications15.
Results
Baseline phenotypic and clinical characteristics of the entire cohort of diabetic patients and stratified by survivors 
and non-survivors are shown in Table 1. The mean age of all T2D patients was 65.8 years, and 54.8% of them were 
men. The population had a mean diabetes duration of 15.3 years (SD 11.4 years) and on average an acceptable 
to good glycemic control (mean HbA1c 7.5%). At the end of an average follow-up duration of 12.08 years, 98 
patients had died (18.1%). Patients who died during the follow-up were older and had significantly higher insulin 
resistance (HOMA-IR), serum levels of glucose, insulin, HbA1c, and average diabetes duration. Moreover, a sig-
nificantly higher prevalence of nephropathy, diabetic retinopathy, and CKD characterized the patients who died 
during the follow-up (Table 1).
Overall survival rates for diabetic patients with higher values of WHR and HbA1c were worse than the other 
patients (Table 2). Diabetes duration also significantly influenced patient survival, with patients having a longer 
diabetes duration living shorter than those with shorter diabetes duration. Furthermore, diabetic patients with 
neuropathy nephropathy, retinopathy, CKD, and anemia lived less than patients without vascular complications 
(Table 2).
Kaplan–Meier survival analysis showed that the overall survival rate of diabetic patients was also correlated 
with five single nucleotide polymorphisms (SNPs) located in or near three different genes: rs1617640-T/G, 
rs507392-T/C, and rs551238-A/C in the EPO gene, rs1121980-C/T in the FTO gene, and rs1800849-C/T in the 
UCP3 gene (see Supplementary Fig. S1 and Table S1). After False Discovery Rate (FDR) correction, association 
Characteristic Total (N = 542)
Survivors 
(N = 444)
Non-survivors 
(N = 98) P-value*
Age (yrs) 65.8 (8.0) 64.8 (7.8) 70.7 (7.3) 1.86*10−11
Gender (% men) 297 (54.8) 236 (53.2) 61 (62.2) 0.102
BMI (kg/m2) 28.9 (4.6) 28.9 (4.5) 29.0 (5.2) 0.756
WHR (mean, SD) 0.93 (0.07) 0.93 (0.07) 0.94 (0.07) 0.069
HOMA-IR (mean, SD) 2.95 (2.85) 2.79 (2.52) 3.69 (3.92) 0.032
Glucose (mean, SD) [mg/dl] 164.5 (48.8) 162.3 (47.9) 174.4 (52.1) 0.026
Insulin (mean, SD) 7.1 (5.6) 6.8 (4.9) 8.4 (8.0) 0.069
Hemoglobin (mean, SD) [mg/dl] 14.3 (1.28) 14.3 (1.62) 14.3 (1.33) 1.000
Anemia (n, %)** 22 (5.0) 11 (11.2) 33 (6.1) 0.019
RBC (mean, SD) 4.72 (0.43) 4.66 (0.52) 4.71 (0.45) 0.200
HbA1c (mean, SD) [%] [mmol/mol] 7.5 (1.3) 57.9 (13.9) 7.4 (1.3) 57.6 (13.9) 7.8 (1.3) 61.4 (13.7) 0.013
Total cholesterol (mean, SD) [mg/dl] 207.2 (37.9) 206.8 (37.2) 207.2 (40.8) 0.923
HDL cholesterol (mean, SD) [mg/dl] 52.3 (14.6) 52.5 (14.2) 51.3 (16.5) 0.505
Diabetes duration (mean, SD) [years] 15.3 (11.3) 14.06 (10.6) 20.9 (12.6) 5.0*10−6
Retinopathy (n, %) 152 (28.0) 111 (25.0) 41 (41.8) 0.001
Nephropathy (n, %) 73 (13.5) 52 (11.7) 21 (21.4) 0.011
Neuropathy (n, %) 101 (18.6) 76 (17.1) 25 (25.5) 0.053
Chronic Kidney Disease (n, %) 20 (3.7) 10 (2.3) 10 (10.2) 1.57*10−4
Table 1. Baseline characteristics of T2D patients stratified according to the occurrence of death during 
follow-up. SD, standard deviation; BMI, Body Mass Index; WHR, waist‐to‐hip ratio; HOMA‐IR, homeostasis 
model assessment of insulin resistance; HbA1c, glycosylated haemoglobin; RBC, Red Blood Cells. *t-test for 
continuous variables; Chi-square test for categorical variables. **Anaemia was defined in accordance with the 
World Health Organization (WHO) criteria (hemoglobin levels <13 g/dL in men and <12 g/dL in women).
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of EPO-variants with survival remained significant (q < 0.10; see Supplementary Table S1). Multivariate Cox 
proportional models were then fitted using age, WHR, HbA1c, diabetes duration, retinopathy, nephropathy, 
CKD, and anaemia as covariates. Once again, we found that variants in the EPO gene remained significantly 
associated with mortality risk at a nominal level of 0.05. As shown in Fig. 1, patients carrying the minor allele 
of rs1617640-(G) and rs507392-(C) had a significantly increased chance of survival with HR values of 0.63 
(95% CI = 0.40–0.98, P-value = 0.039) and 0.58 (95%CI = 0.37–0.92, P-value = 0.020), respectively. There was 
a trend for a positive association with survival also for carriers of the minor allele of rs551238-(C) (HR = 0.66, 
95%CI = 0.42–1.03, P-value = 0.065).
LD analysis showed a high degree of disequilibrium among the three EPO SNPs (r2 > 0.97), meaning that 
the associations are not independent. As such, haplotype analysis was performed to further explore the rela-
tionship between EPO variations and diabetes mortality risk. Out of the eight possible haplotypes, two, T-T-A 
(major allele combination, 67.0%) and G-C-C (minor allele combination, 32.2%), were the most common in 
our study samples. As shown in Fig. 2, haplotype multivariate survival analysis corroborated the single-locus 
analyses. While the presence of the T-T-A haplotype was found to decrease the chance of survival, carriers of 
the G-C-C haplotype showed a significantly increased survival chance with respect to non-carriers (HR = 0.63, 
95%CI = 0.41–0.99, P-value = 0.044).
Discussion
Patients with T2D have higher all-cause mortality risk than matched individuals without diabetes16,17. 
Epidemiological studies have identified several demographic, socioeconomic, and biological independent predic-
tors of mortality in T2D patients8,18, but only a few of them have evaluated the role of genetic factors. In agreement 
with the current literature, this study identified age, WHR, HbA1c, diabetes duration, retinopathy, nephropa-
thy, CKD, and anaemia as predictors of all-cause mortality. Additionally, after adjusting for the effects of these 
risk factors, our results showed that three EPO genetic variants in high LD (rs1617640-T/G, rs507392-T/C and 
rs551238-A/C) were associated with all-cause mortality risk in both single-SNP and haplotype-based analyses.
The EPO gene encodes erythropoietin, which is a kidney-derived cytokine that plays a major role in pro-
moting erythropoiesis, in particular in response to hypoxic stress19. However, recent evidence shows that 
EPO is also expressed locally in others tissues and organs, including peripheral endothelial cells, muscle, and 
insulin-producing cells, where it displays anti-apoptotic, anti-inflammatory, and angiogenic effects due to its abil-
ity to activate several transduction signalling pathways20–23. A growing literature argues for a critical role of EPO 
in diabetes and its complications24. For example, Fenjves et al. demonstrated that EPO overexpression in human 
islet cells provides protection from cell death25. Studies in model organisms also suggest that EPO can protect 
against diabetes through a direct effect on β cells26, and possibly through the modulation of glucose metabolism, 
glucose tolerance, and insulin sensitivity27. Furthermore, Abhary and colleagues identified three genetic vari-
ants in EPO associated with a higher risk to develop diabetic retinopathy28. Although no significant associations 
between EPO SNPs and T2D or its vascular complications were identified in our earlier analysis15, the findings in 
this study corroborate the close and complex link between erythropoietin and diabetes status.
A weakness of this study is that the specific causes of death were not determined during follow-up, preventing 
us from conducting an in-depth evaluation of the association of the investigated SNPs with the mortality risk 
in diabetic patients. Also, the mechanism through which the EPO TTA haplotype increases mortality in T2D 
patients is unknown at this time. However, it is important to point out that Tong and colleagues previously found 
that the EPO rs1617640-T allele is associated with a 25-fold higher promoter activity compared with the G allele, 
suggesting that this SNP plays a significant functional role in EPO expression29. Taken together with our results 
this observation suggests that high levels of erythropoietin may have detrimental effects in patients with T2D. 
Variable HR (95% CI) P-value
Age 1.11 (1.08–1.14) <0.001
Gender (men) 1.39 (0.92–2.09) 0.116
BMI* 1.07 (0.72–1.59) 0.750
WHR* 1.51 (1.01–2.26) 0.046
HbA1c* 1.50 (1.01–2.23) 0.045
Anaemia 2.53 (1.35–4.73) 0.004
HOMA-IR* 1.48 (0.99–2.22) 0.056
Insulin* 1.16 (0.77–1.74) 0.489
Glucose* 1.41 (0.95–2.10) 0.087
Diabetes duration (>10 yrs) 2.48 (1.51–4.09) <0.001
Retinopathy 1.94 (1.30–2.90) 0.001
Nephropathy 1.82 (1.12–2.95) 0.015
Neuropathy 1.58 (1.00–2.49) 0.049
Chronic Kidney Disease 3.71 (1.93–7.15) <0.001
Table 2. Hazard ratios for all-cause mortality for baseline characteristics. BMI, Body Mass Index; WHR, 
waist‐to‐hip ratio; HbA1c, glycosylated haemoglobin; HOMA‐IR, homeostasis model assessment of insulin 
resistance. *Sample mean used as a cut-off value.
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This idea is supported by several pieces of evidence. Elevated erythropoietin concentrations have been linked 
to proliferative diabetic retinopathy, which in turn is associated with excessive vascular growth30. A study by 
Wagner and colleagues also showed that in diabetic patients with CKD, elevated endogenous EPO levels were 
predictive of all-cause mortality and related mainly to markers of inflammation independently of kidney function 
and haemoglobin levels31. Similar results were observed in people aged 85 years and older32 and in patients with 
heart failure33,34. Given that our analysis did not detect any correlation between the studied EPO SNPs and the 
presence/absence of anaemia (data not shown), it is plausible that inflammation, a key emerging risk factor for 
T2D, is a potential mechanism linking EPO and mortality in T2D patients.
It has been shown that EPO acts as a proliferative factor and thereby can promote tumor growth and metas-
tasis35. Ongoing studies indicate that the use of EPO for the treatment of cancer-induced anaemia is related to an 
increased incidence of cancer progression and reduced survival of patients36. Epidemiologic evidence indicates 
Figure 1. Survival functions of carriers of minor allele (black) vs non carriers (grey) of EPO variants. 
(A) rs1617640; (B) rs507392; (C) rs551238. Time is expressed in years, where 0 is considered the time of 
recruitment. The Cox regression was adjusted for age, gender WHR, HbA1c, anaemia, diabetes duration, and 
diabetes complications. HR value, confidence interval, and p-value from Cox regression analysis are reported 
inside the figure.
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that diabetes is associated with increased risk of many types of cancer37; therefore, it is also possible that higher 
levels of EPO might contribute to the increased risk of mortality in diabetic patients because of an increased 
incidence of cancer. In this regard, it is notable that an EPO polymorphism (rs576236) in LD with those here 
investigated confers susceptibility to adrenal tumor38.
In conclusion, this study identified an EPO haplotype that increases the risk of mortality among patients with 
T2D, independently of non-genetic risk factors. Over the last 30 years, it has become clear that erythropoietin 
possesses several tissue-specific functions that go far beyond the regulation of red cell production; therefore, 
further studies are needed to elucidate the molecular mechanisms linking EPO and mortality in diabetic patients. 
The elucidation of the mechanisms underlying the observed genetic associations could not only enhance our 
understanding of the molecular and genetic basis of the disease but also provide valuable insights into potential 
targets for therapeutic interventions aimed at increasing the survival of diabetic patients.
Methods
Study population and genetic data. Classification criteria and details of the cohort as well as the genetic 
data used in this study were previously reported15. Briefly, the sample includes 542 individuals with T2D (mean 
age 65.8 ± 8.0), collected by the Diabology Unit, INRCA (National Institute on Health and Science on Aging) 
in Ancona (Italy). Briefly, demographic, anthropometric and clinical data were collected for each individual 
and recorded in a well-defined questionnaire. The presence/absence of diabetic complications was evidenced 
as follows: diabetic retinopathy by fundoscopy through dilated pupils and/or fluorescence angiography; incipi-
ent nephropathy, defined as an urinary albumin excretion rate > 30 mg/24 h and a normal creatinine clearance; 
CKD, defined as an estimated glomerular filtration rate <60 mL/min per 1.73 m2; neuropathy was established by 
electromyography.
Ethical approval for this study has been granted by the Ethics Committee of National Institute on Health and 
Science on Aging (INRCA). All participants gave written informed consent. All methods were performed in 
accordance with the relevant guidelines and regulations.
The genetic data includes 40 SNPs located in or near 21 candidate genes. However, nine SNPs were excluded 
from the analysis because they had either a high proportion of missing genotypes (call rate lower than 90%; 
rs669173, rs2853669, rs4880, rs13266634, rs7901695, rs8047395) or a minor allele frequency (MAF) lower than 
5% (rs3811791, rs16889462, rs2237892). The final dataset included 31 high-quality SNPs that were tested for 
association with survival (see Supplementary Table S1).
Outcome. The main outcome of our study was all-cause mortality. The average follow-up duration was 12.08 
years (range 1.41–13.66 years). At each follow-up visit, information was collected on vital status, functional status, 
and occurrence of diabetes complications. For patients who died during the follow-up period, information about 
date and place of death were collected from death certificates provided by relatives or caregivers. City or town 
registers were consulted to retrieve information about death when death certificates were not provided. After this 
period 61 men (20.5%) and 37 women (15.1%) died.
Analytic approach. Unpaired t-test and chi-square were performed for continuous and categorical variables, 
respectively, to compare variables and covariates between dead and survived patients at the end of the follow-up 
period. Cox regression models were used to evaluate the effect of anthropometric and haematological parameters, 
anaemia, diabetes duration, and diabetes complications on mortality. The length of survival from baseline visit 
until death was used as failure time for the models. Survivors were censored on the day of the last follow-up visit. 
The proportional hazard assumption was checked graphically, plotting the log-minus-log survival function over 
time. Kaplan-Meier analysis was performed to estimate survival curves stratified for each SNP. To control for the 
false-positive rate, the FDR method was used; the cut-off of the FDR adjusted p-value (q-value) was 0.10.
Figure 2. Survival functions of carriers (black) vs non carriers (grey) of the G-C-C haplotype of EPO. Time 
is expressed in years, where 0 is considered the time of recruitment. The Cox regression model was adjusted 
for age, gender WHR, HbA1c, anaemia, diabetes duration, and diabetes complications. HR value, confidence 
interval and p-value from Cox regression analysis are reported inside the figure.
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Covariates significantly associated with survival (p < 0.05) in the univariate analyses were included as con-
founding factors in the multivariate Cox proportional hazards models. These models were used to identify SNPs/
haplotypes significantly associated with all-cause mortality. In all analyses, genetic data were coded using a dom-
inant model (carriers for the minor allele versus non-carriers).
Pairwise measures of LD between the analyzed loci were calculated with the Haploview 4.239. The amount of 
LD was quantified by Lewontin’s coefficient (D’).
Statistical analyses were performed using the survival package of R v3.4.2 statistical language (R Foundation 
for Statistical Computing, Vienna, Austria, www.r-project.org).
Data Availability
The dataset analysed during the current study is available from the corresponding author on reasonable request.
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